Details

Autor(en) / Beteiligte

• Larsen, Trine-Lise
• Ghanima, Waleed
• Sandset, Per Morten
• Frøen, Hege
• Jacobsen, Eva-Marie
• Torfoss, Dag
• Dahm, Anders Erik Astrup

Titel

Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients

Ist Teil von

• Tidsskrift for den Norske Lægeforening, 2023-01, Vol.142 (1)

Ort / Verlag

Norway

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Venous thromboembolism is a common complication of cancer. The prevalence varies according to cancer type and increases proportionally with the stage of cancer. In the past 15-20 years, low molecular weight heparin has been recommended as the first-line treatment. New international guidelines now allow for use of direct factor Xa inhibitors both as prophylaxis and treatment for venous thromboembolism. Prophylaxis should as a general rule only be initiated in patients with moderate to high risk. Bleeding risk assessment is important before starting anticoagulation. Both thrombosis and bleeding risk can change and should therefore be assessed on an ongoing basis. In this clinical review, use of anticoagulation therapy in cancer patients is discussed with particular emphasis on the use of direct factor Xa inhibitors.